Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Return on Equity (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Return on Equity for 4 consecutive years, with 0.24% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 15.0% to 0.24% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.24%, a 15.0% increase, with the full-year FY2025 number at 0.23%, changed 0.0% from a year prior.
  • Return on Equity was 0.24% for Q4 2025 at Day One Biopharmaceuticals, up from 0.33% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.2% in Q2 2025 to a low of 0.91% in Q2 2024.
  • A 4-year average of 0.45% and a median of 0.43% in 2023 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -46bps in 2024, then skyrocketed 71bps in 2025.
  • Day One Biopharmaceuticals' Return on Equity stood at 0.41% in 2022, then fell by -25bps to 0.51% in 2023, then grew by 25bps to 0.39% in 2024, then soared by 38bps to 0.24% in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Return on Equity are 0.24% (Q4 2025), 0.33% (Q3 2025), and 0.2% (Q2 2025).